- Top of page
Aims Quinine is often used to prevent muscle cramps in patients with chronic renal failure. A standard dose of 300 mg at bedtime is usually recommended, but little is known about the pharmacokinetics of quinine in the presence of renal failure.
Methods We studied the pharmacokinetics of quinine in eight normal subjects and eight patients with chronic renal failure on haemodialysis after a single oral dose of quinine sulphate (300 mg).
Results The concentration of α1-acid glycoprotein (AAG), the major binding protein for quinine, was increased in haemodialysis patients compared with control subjects (1.52 g l−1vs 0.63 g l−1[mean difference 1.033; 95% CI 0.735, 1.330]) whereas albumin levels were decreased (30 g l−1vs 40 g l−1[mean difference 9.5; 95% CI 3.048, 15.952]). Accordingly, the free fraction of quinine was decreased (0.024 vs 0.063 [mean difference 0.0380; 95% CI 0.0221, 0.0539]) and the apparent volume of distribution tended to decrease (0.95 l kg−1vs 1.43 l kg−1[mean difference 0.480; 95% CI 0.193, 1.154]). The quinine binding ratio correlated with the plasma concentration of AAG but not that of albumin. The clearance of free (unbound) quinine was increased in haemodialysis patients compared with controls (67.9 ml min−1 kg−1vs 41.1 ml min−1 kg−1[mean difference −26.8; 95% CI, –56.994, 3.469]), and the area under the curve (AUC) of the two main metabolites, 3-hydroxyquinine and 10,11-dihydroxydihydroquinine were increased.
Conclusions In patients with chronic renal failure, there is an increase in plasma protein binding and in the clearance of free drug, resulting in lower plasma concentration of free quinine.
- Top of page
Quinine is often used for the prevention and treatment of muscle cramps. A meta-analysis of randomized clinical trials evaluating its efficacy for the relief of nocturnal leg cramps supports its use for this indication . Quinine and its diastereomer quinidine are thought to act by decreasing the excitability of the myoneuronal plate and by increasing the refractory period of striated muscle [2, 3]. The effect of quinine or quinidine appears to be dose-related: Lee et al. have shown a significant relationship between serum quinidine concentration and attenuation of cramps, and trials using a larger dose of quinine (500 mg) have shown better efficacy than those using a lower dose (200 mg) [5–7].
In patients with chronic renal failure, muscle cramps occur most frequently during haemodialysis sessions and may be relieved by hypertonic saline or dextrose solutions administered intravenously . Cramps may also be prevented by prazosin , although clinically significant hypotensive episodes are a major drawback to its regular use. Quinine remains the most commonly used agent to prevent cramps in patients with chronic renal failure. Controlled trials have shown that quinine reduces the frequency and severity of muscle cramps in haemodialysis patients [10, 11]. A standard dose of 300 mg quinine at bedtime is most often used, although not uniformly effective. No data are available on the pharmacokinetics of quinine in patients with severe chronic renal failure. Quinine is a weak base that is highly bound to α1-acid glycoprotein (AAG) in plasma [12–14]. AAG plasma concentration is known to be increased in chronic renal failure , and this could result in lower plasma concentration of free (unbound) quinine and reduced efficacy. The purpose of the present study was to define the pharmacokinetics of a single dose of quinine in chronic haemodialysis patients as compared with healthy volunteers.
- Top of page
The characteristics of the two groups studied are reported in Table 1. Haemodialysis patients were older than controls, had lower serum albumin and higher serum AAG concentrations. Liver function tests were normal in both groups (data not shown).
Table 1. Characteristics of controls and haemodialysis patients
| || Controls (n = 8)|| Haemodialysis (n = 8)||P value|
|Gender (male : female)||5 : 3||5 : 3|| |
|Age (years)||38 ± 9||58 ± 13||0.003|
|Weight (kg)||71 ± 13||68 ± 14||0.798|
|Serum creatinine (µmol l−1)||84 ± 16||625 ± 206||0.001|
|Serum albumin (g l−1)||40 ± 3||30 ± 7||0.022|
|Serum AAG (g l−1)||0.63 ± 0.15||1.52 ± 0.60||0.010|
The mean plasma concentration vs time curves for quinine and its metabolites in control subjects and haemodialysis patients are shown in Figure 1 and pharmacokinetic parameters are presented in Table 2. Cmax was significantly higher in haemodialysis patients whereas tmax was similar in the two groups (1.6 ± 0.7 vs 1.9 ± 0.4 h). The oral total clearance of quinine was decreased by 43% in haemodialysis patients. The clearance by the dialysis apparatus was poor with an extraction of 6.4 ± 5.5%. The volume of distribution of quinine appeared to decrease in haemodialysis patients as compared with controls, but this difference was not significant (P = 0.08).
Figure 1. Mean total plasma concentration vs time curves for quinine (●), 3-hydroxy-quinine (3-OH-Q) (), and 10–11-dihydroxy-dihydro-quinine (10–11-Q) (□) in control subjects and haemodialysis patients.
Download figure to PowerPoint
Table 2. Pharmacokinetic parameters of quinine disposition, protein-binding of quinine and metabolism of quinine in control subjects and haemodialysis patients
| || Controls || Haemodialysis ||P value|
| Quinine disposition |
| C max (µg ml−1)||2.60 ± 0.99||4.56 ± 1.58||0.004|
|CLo (ml min−1 kg−1)||2.51 ± 1.59||1.41 ± 0.63||0.033|
| V d area (l kg−1)||1.43 ± 0.78||0.95 ± 0.29||0.080|
| K el (h−1)||0.106 ± 0.031||0.090 ± 0.023||0.221|
| t 1/2 (h)||7.02 ± 1.72||8.26 ± 2.10||0.382|
| Protein-binding of quinine |
|Free fraction||0.063 ± 0.014||0.024 ± 0.015||0.001|
|(Bound/Free) AAG (l g−1)|| 26.0 ± 6.0||31.0 ± 13.4||0.191|
|(Bound/Free) albumin (l g−1)||0.4 ± 0.1||1.6 ± 0.4||0.001|
|Free CLo (ml min−1 kg−1)||41.1 ± 24.0||67.9 ± 32.0||0.033|
| Metabolism of quinine |
|Free fraction||0.063 ± .014||0.024 ± .015||0.001|
|AUC free quinine|| 2.11 ± 1.04|| 1.40 ± .55||0.080|
|AUC3-OH-Q|| 12.9 ± 4.3||45.1 ± 51.3||0.083|
|AUC10−11-Q||2.42 ± 0.89||4.46 ± 1.07||0.003|
|Ratio 3-OH-Q/free quinine||6.80 ± 2.12||46.30 ± 74.38||0.049|
|Ratio 10–11-Q/free quinine|| 1.36 ± .66||4.12 ± 3.04||0.002|
The free fraction of quinine was markedly decreased in haemodialysis patients (Table 2). The ratio (bound/free)/AAG was similar in the two groups and the correlation between bound/free ratio and AAG concentration was good (r = 0.789, P = 0.001). On the other hand, the ratio (bound/free)/albumin was higher in haemodialysis patients, but the correlation between the ratio and albumin concentration was poor (r = 0.234). Plasma concentrations of free quinine were lower and the oral free clearance was increased in haemodialysis patients compared with control subjects (Figure 2 and Table 2). The relationship between the plasma concentration of quinine and its metabolites is summarized in Table 2. The AUC for free quinine was significantly lower, and the ratio of AUC10,11-Q/AUCfree quinine and AUC3OH-Q/AUCfree quinine were significantly increased in haemodialysis patients compared with control subjects.
Figure 2. Plasma concentration (mean ± s.d.) vs time curves for free quinine in control subjects (●) and haemodialysis patients ().
Download figure to PowerPoint
- Top of page
Quinine pharmacokinetics has not been studied previously in patients with severe renal failure, although this drug is frequently used to prevent and treat muscle cramps associated with dialysis. In the present study, a group of haemodialysis patients was compared with healthy volunteers.
The absorption phase seemed altered in haemodialysis patients. Quinine is a weak base (pKa 8.4) and it is best absorbed when the gastric pH is high. In a more alkaline solution, the ratio of unionized to ionized quinine will be higher, promoting absorbtion. In patients with severe renal failure, the gastric pH may increase due to the presence of ammonia, derived from urea present in swallowed saliva and cleaved by gastric urease . This could explain an increased absorption of quinine and a lower absorption of acidic drugs in haemodialysis patients. Other causes of altered absorption in severe renal failure include drug interactions, oedematous state and gastroparesis , none of which was present in our patients. An alternative explanation for the increased Cmax is the smaller apparent volume of distribution in haemodialysis patients.
In haemodialysis patients, there was an important decrease in the free fraction of quinine which was related to an increased serum concentration of AAG. This acute-phase reactant protein is known to be increased in chronic renal failure . Quinine is mostly bound to AAG and much less to albumin [12–14]. Uraemia may alter drug-binding to albumin not only by a decrease in serum albumin concentration, but also by competitive displacement of the drug from its binding sites by accumulated substances, or by a change in the structural configuration of the binding sites . Drug binding to AAG however, appears to depend almost exclusively on its serum concentration in uraemic patients . In the present study, we observed a good correlation between quinine binding and the plasma concentration of AAG but not that of albumin, in both normal and haemodialysis subjects. Thus, quinine binding to AAG depends mostly on the binding protein concentration whereas quinine binding to albumin may be influenced by factors other than serum albumin concentration.
Quinine is eliminated almost exclusively by hepatic metabolism. Since quinine has a low hepatic extraction ratio, the binding is rate limiting for its hepatic uptake. Thus free (unbound) drug is available for hepatic uptake and metabolism, and free clearance is an appropriate measure of its rate of elimination. In haemodialysis patients, the clearance of free quinine was increased compared with controls. The elimination of other drugs such as propranolol and phenytoin has also been shown to be increased in uraemic patients . The mechanism responsible for this increased hepatic elimination remains unclear. Quinine is metabolized by oxidation of the quinoline or the quinuclidine moieties into four primary metabolites and at least 11 secondary metabolites . Cytochrome P4503A catalyses the formation of 3-OH-quinine , but the enzymes responsible for the formation of the other metabolites have not been identified. In our h.p.l.c. assay, two of the primary metabolites of quinine could be identified and quantified. There was an increase in the plasma concentration of both 3-OH-quinine and 10,11-dihydroxydihydroquinine in haemodialysis patient which could be related to increased formation of the metabolites and/or decreased renal elimination. None of the patients included in the study was receiving drugs known to induce cytochrome P450, but enzyme induction has been postulated in uraemic patients due to external agents such as plasticizers in haemodialysis tubing .
In summary, two major changes were seen in haemodialysis patients. The first relates to the binding of quinine, which is increased because of elevated serum concentrations of AAG. The second is an increase in the clearance of free drug, resulting in lower plasma concentrations of free quinine. The efficacy of quinine to prevent muscular cramps appears to be dose-related, and our data show that patients with severe chronic renal failure may have a lower free concentration of quinine; further studies are needed to confirm that patients who do not experience an improvement in the severity or frequency of muscular cramps may benefit from a larger dose.